Effect of trimetazidine on recurrent angina pectoris and left ventricular structure in elderly multivessel coronary heart disease patients with diabetes mellitus after drug-eluting stent implantation: A single-centre, prospective, randomized, double-blind study at 2-year follow-up

Clinical Drug Investigation

Volumn 34, Issue 4, 2014, Pages 251-258

  Xu, Xiaohan ^a   Zhang, Weijun ^a   Zhou, Yujie ^a   Zhao, Yingxin ^a   Liu, Yuyang ^a   Shi, Dongmei ^a   Zhou, Zhiming ^a   Ma, Hanying ^a   Wang, Zhijian ^a   Yu, Miao ^a   Ma, Qian ^a   Gao, Fei ^a   Shen, Hua ^a   Zhang, Jianwei ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ENDEAVOR; FIREBIRD; PACLITAXEL; PLACEBO; RAPAMYCIN; TRIMETAZIDINE; UNCLASSIFIED DRUG; ZOTAROLIMUS; VASODILATOR AGENT;

AGED; ANGINA PECTORIS; ARTICLE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY RECANALIZATION; CORONARY STENT; DIABETIC PATIENT; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG ELUTING STENT; ECHOCARDIOGRAPHY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GERIATRIC PATIENT; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PACLITAXEL ELUTING STENT; POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT ANGINA PECTORIS; RECURRENT DISEASE; SIROLIMUS ELUTING STENT; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ZOTAROLIMUS ELUTING STENT; COMPLICATION; CORONARY DISEASE; DIABETES COMPLICATIONS; DRUG EFFECTS; SECONDARY PREVENTION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGINA PECTORIS; CORONARY DISEASE; DIABETES COMPLICATIONS; DOUBLE-BLIND METHOD; DRUG-ELUTING STENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; SECONDARY PREVENTION; TREATMENT OUTCOME; TRIMETAZIDINE; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 84898826331     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-014-0170-9     Document Type: Article

References (22)

1. Yusuf S, Reddy S, Ounpuu S, et al. Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation. 2001;104:2746-53.
2. Danchin N, Marzilli M, Parkhomenko O, et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology. 2011;120:59-72.
3. Hanania G, Cambou JP, Guéret P, et al. Management and in-hospital outcome of patients with acute myocardial infarction admitted to intensive care units at the turn of the century: results from the French nationwide USIC 2000 registry. Heart. 2004;90:1404-10.
4. Pfisterer M, Buser P, Osswald S, et al. Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. JAMA. 2003;289:1117-23.
5. Hueb W, Soares PR, Gersh BJ, et al. The Medicine, Angioplasty, or Surgery trial (MASS-II): a randomized, controlled, clinical trial of three therapeutic strategies for multivessel coronary artery disease. One-year results. J Am Coll Cardiol. 2004;43:1743-51.
6. Gersh BJ. Coronary revascularization for angina pectoris in the elderly. Rev Cardiovasc Med. 2003;4:55-8.
7. Hu B, Li W, Xu T, et al. Evaluation of trimetazidine in angina pectoris by echocardiography and radionuclide angiography: a meta-analysis of randomized, controlled trials. Clin Cardiol. 2011;34:395-400.
8. Gao D, Ning N, Niu X, et al. Trimetazidine: a meta-analysis of randomised controlled trials in heart failure. Heart. 2011;97:278-86.
9. Nathan DM, Buse JB, Davidson MB, et al. American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32:193-203.
10. Zhang L, Lu Y, Jiang H, et al. Additional use of trimetazidine in patients with chronic heart failure: a meta-analysis. J Am Coll Cardiol. 2012;59:913-22.
11. Fragasso G, Rosano G, Baek SH, et al. Effect of partial fatty acid oxidation inhibition with trimetazidine on mortality and morbidity in heart failure: results from an international multicentre retrospective cohort study. Int J Cardiol. 2013;163:320-5.
12. Henderson RA, Pocock SJ, Clayton TC, et al. Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical treatment. J Am Coll Cardiol. 2003;42:1161-70.
13. Vitale C, Spoletini I, Malorni W, et al. Efficacy of trimetazidine on functional capacity in symptomatic patients with stable exertional angina - the VASCO-angina study. Int J Cardiol. 2013;168:1078-81.
14. Bucci M, Borra R, Någren K, et al. Trimetazidine reduces endogenous free fatty acid oxidation and improves myocardial efficiency in obese humans. Cardiovasc Ther. 2012;30:333-41.
15. Fragasso G, Salerno A, Lattuada G, et al. Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure. Heart. 2011;97:1495-500.
16. Zhou X, Li C, Xu W, et al. Trimetazidine protects against smoking-induced left ventricular remodeling via attenuating oxidative stress, apoptosis, and inflammation. PLoS One. 2012;7:e40424.
17. 2-induced injury: involvement of antioxidation and Akt/eNOS signaling pathways. Eur J Pharmacol. 2013;707:87-94.
18. Dehina L, Vaillant F, Tabib A, et al. Trimetazidine demonstrated cardioprotective effects through mitochondrial pathway in a model of acute coronary ischemia. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:205-15.
19. Vitale C, Wajngaten M, Sposato B, et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J. 2004;25:1814-21.
20. Zhao P, Zhang J, Yin XG, et al. The effect of trimetazidine on cardiac function in diabetic patients with idiopathic dilated cardiomyopathy. Life Sci. 2013;92:633-8.
21. Bonow RO. The hibernating myocardium: implications for management of congestive heart failure. Am J Cardiol. 1995;75:17A-25A.
22. Aurigemma GP, Gottdiener JS, Shemanski L, et al. Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the Cardiovascular Health Study. J Am Coll Cardiol. 2001;37:1042-8.